Pitcairn Co. Sells 7,539 Shares of DexCom, Inc. $DXCM

Pitcairn Co. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 42.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,399 shares of the medical device company’s stock after selling 7,539 shares during the quarter. Pitcairn Co.’s holdings in DexCom were worth $700,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Andra AP fonden purchased a new stake in shares of DexCom during the second quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in shares of DexCom in the 2nd quarter worth approximately $26,000. SJS Investment Consulting Inc. raised its stake in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares in the last quarter. Financial Consulate Inc. bought a new position in shares of DexCom during the 3rd quarter worth approximately $29,000. Finally, Sound Income Strategies LLC lifted its position in DexCom by 83.8% during the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 285 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM opened at $68.10 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The company’s fifty day moving average price is $70.69 and its 200-day moving average price is $68.84. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98. The firm has a market capitalization of $26.21 billion, a PE ratio of 32.43, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter last year, the business posted $0.45 EPS. On average, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday. Robert W. Baird set a $87.00 target price on DexCom in a research report on Friday, February 13th. Leerink Partners reiterated an “outperform” rating and issued a $92.00 price target on shares of DexCom in a research note on Tuesday, December 16th. Piper Sandler reissued an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Finally, Canaccord Genuity Group set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $85.18.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.